Rhenman & Partners Asset Management’s Nurix Therapeutics NRIX Stock Holding History

Rhenman & Partners Asset Management’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.6M	Buy	684,250 +370,750	+118%	+$6.32M	1.57%	19
2026 Q1	$4.86M	Sell	313,500 -224,000	-42%	-$3.71M	0.6%	57
2025 Q4	$10.2M	Buy	537,500 +190,000	+55%	+$2.73M	0.95%	41
2025 Q3	$3.21M	Buy	347,500 +162,500	+88%	+$1.69M	0.36%	73
2025 Q2	$2.11M	Sell	185,000 -64,336	-26%	-$695K	0.27%	71
2025 Q1	$2.96M	Sell	249,336 -40,664	-14%	-$680K	0.34%	61
2024 Q4	$5.46M	Sell	290,000 -10,000	-3%	-$229K	0.56%	55
2024 Q3	$6.74M	Buy	300,000 +125,607	+72%	+$2.85M	0.55%	58
2024 Q2	$3.64M	Buy	+174,393	New	+$2.72M	0.35%	65

Other funds holding NRIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Rhenman & Partners Asset Management's NRIX Position: Q2 2026 in Review

Rhenman & Partners Asset Management increased its Nurix Therapeutics (NRIX) stake by 118% in Q2 2026, buying an estimated $6.32M and bringing the position to 684,250 shares worth $16.6M. The position accounts for 1.57% of the portfolio, ranked #19.

Rhenman & Partners Asset Management first reported a position in NRIX in Q2 2024 and has held it in 9 quarters since. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

Rhenman & Partners Asset Management held 684,250 shares of Nurix Therapeutics worth $16.6M as of Q2 2026.
Rhenman & Partners Asset Management bought 370,750 Nurix Therapeutics shares in Q2 2026, an estimated $6.32M.
Nurix Therapeutics made up 1.57% of Rhenman & Partners Asset Management's portfolio in Q2 2026, its #19 holding.
Rhenman & Partners Asset Management first reported a position in Nurix Therapeutics in Q2 2024 and has held it in 9 quarters since.
211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.